N. Anthony Coles, Director at REGENERON PHARMACEUTICALS, INC. (REGN), sold 11,415 shares at $707.87 ($8.2M) on 2022-12-28, disclosed to the SEC on 2022-12-30.
Open-market sale of $8.2M REGN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $707.87 | 181 | $128K | 1.6% |
| 2 | $707.87 | 181 | $128K | 1.6% |
| 3 | $709.92 | 1 | $710 | 0.0% |
| 4 | $710.63 | 679 | $483K | 5.9% |
| 5 | $710.63 | 679 | $483K | 5.9% |
| 6 | $711.95 | 100 |
| $71K |
| 0.9% |
| 7 | $713.66 | 1,198 | $855K | 10.5% |
| 8 | $713.66 | 1,198 | $855K | 10.5% |
| 9 | $714.61 | 1,022 | $730K | 9.0% |
| 10 | $714.61 | 1,022 | $730K | 9.0% |
| 11 | $715.48 | 2,266 | $1.6M | 19.9% |
| 12 | $715.48 | 2,266 | $1.6M | 19.9% |
| 13 | $716.08 | 311 | $223K | 2.7% |
| 14 | $716.08 | 311 | $223K | 2.7% |
| Total | $714.13 avg | 11,415 | $8.2M | 100% |
| Filing → |
| CERE | SELL | 2024-05-14 | $2.1M | — | Filing → |
| CERE | SELL | 2024-04-03 | $2.1M | — | Filing → |
| CERE | SELL | 2024-03-06 | $2.1M | — | Filing → |